Turtle Cameron's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Aug 5, 2026
- Accession no.
- 0001636282-26-000099
- Filed
- Aug 5, 2026, 9:31 PM ET
- Trade date
- Aug 3, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.43M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Turtle CameronCIK 0001758363 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Common Stock | SSaleDisposed | −800 | $93.97 | −$75,176 | 581,740 | Direct | |
| Aug 3, 2026 | Common Stock | SSaleDisposed | −7,157 | $95.10 | −$680,630.7 | 574,583 | Direct | |
| Aug 3, 2026 | Common Stock | SSaleDisposed | −5,635 | $95.93 | −$540,565.55 | 568,948 | Direct | |
| Aug 3, 2026 | Common Stock | SSaleDisposed | −1,392 | $96.82 | −$134,773.44 | 567,556 | Direct | |
| Aug 3, 2026 | Common Stock | SSaleDisposed | −16 | $97.46 | −$1,559.36 | 567,540 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.